GENFIT

The Lille-based biotech company specializing in hepatic and metabolic diseases extends its decline this Tuesday, following the publication of its first-half 2026 results. Despite solid cash reserves and royalties in sharp progression, the market penalizes

Lille (France), Cambridge (Massachusetts, États-Unis), le 28 septembre 2026 - GENFIT (Euronext: GNFT), société biopharmaceutique de stade clinique avancé engagée dans l'amélioration de la vie des patients atteints de maladies rares du foie pouvant engager

Detailed price information for Genfit (GNFTF) from The Globe and Mail including charting and trades.

Detailed price information for Genfit (GNFTF) from The Globe and Mail including charting and trades.

Financial Highlights Cash and cash equivalents totaled €113.8 million as of June 30, 2026; expected to fund the Company beyond the end of 2028€21.1 million in revenues as of June 30, 2026, including

In conjunction with (i) the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, and (ii) the final terms of the dual proposal to the 2025 OCEANEs holders announced on February 10, 2025, GENFIT will seek the consent of the

Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.